Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2916607 | 1.00 | CYP2D6 (0.61) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL9596277 | 1.00 | CYP2D6 (0.61) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| Ethane SCHEMBL9682617 | 0.98 | CYP2D6 (0.59) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| Fumaric Acid SCHEMBL9596362 | 0.88 | CYP2D6 (0.49) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| Maleic Acid SCHEMBL9596354 | 0.88 | CYP2D6 (0.49) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL5275767 | 0.85 | CYP2D6 (0.58) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL9137138 | 0.85 | CYP2D6 (0.58) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL6097455 | 0.83 | CYP2D6 (0.65) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL2916278 | 0.82 | HSD11B1 (0.46) | CYP2D6OPRM1HSD11B1 | |
| SCHEMBL19614197 | 0.81 | CYP2D6 (0.68) | CYP2D6MC4ROPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| CN-101643470-B | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO LTD | 2012-08-01 | — | — | CN | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100274003-A1 | ACID ADDITION SALTS OF SYNTHETIC INTERMEDIATES FOR CARBAPENEM ANTIBIOTICS AND PROCESSES FOR PREPARING THE SAME | Kukje Pharm Ind co. Ltd (KR) | 2010-10-28 | — | — | US | disclosed |
| EP-1784407-B1 | 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF | KOREA RES INST CHEM TECH (KR) | 2010-09-08 | — | — | EP | disclosed |
| EP-2188287-A2 | ACID ADDITION SALTS OF SYNTHETIC INTERMEDIATES FOR CARBAPENEM ANTIBIOTICS AND PROCESSES FOR PREPARING THE SAME | Kukje Pharm. Ind. Co., Ltd. (KR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009038328-A2 | ACID ADDITION SALTS OF SYNTHETIC INTERMEDIATES FOR CARBAPENEM ANTIBIOTICS AND PROCESSES FOR PREPARING THE SAME | KUKJE PHARM. IND. CO., LTD. (KR) | 2009-03-26 | — | — | WO | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-20070244089-A1 | 2- Arylmethylazetidine Carbapenem Derivatives and Preparation Thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-10-18 | — | — | US | disclosed |
| EP-1437353-B1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-7087594-B2 | central nervous system disorders; regenerating nervous systems | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | CYP2D6 4089/4885MC4R 4649/4885OPRM1 1485/4885 |
| US-20100274003-A1 | ACID ADDITION SALTS OF SYNTHETIC INTERMEDIATES FOR CARBAPENEM ANTIBIOTICS AND PROCESSES FOR PREPARING THE SAME | SLC7A5, SI, ADSL | CYP2D6 2244/4885MC4R 4366/4885OPRM1 4388/4885 |
| US-20070244089-A1 | 2- Arylmethylazetidine Carbapenem Derivatives and Preparation Thereof | SCN9A, SCN2A, SCN5A | CYP2D6 170/4885MC4R 2462/4885OPRM1 837/4885 |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | CYP2D6 4089/4885MC4R 4649/4885OPRM1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.